CRASH-3 Publications

A nested mechanistic sub-study into the effect of tranexamic acid versus placebo on intracranial haemorrhage and cerebral ischaemia in isolated traumatic brain injury: study protocol for a randomised controlled trial (CRASH-3 Trial Intracranial Bleeding Mechanistic Sub-Study [CRASH-3 IBMS])

Abda Mahmood, Ian Roberts, Haleema Shakur-Still

Trials

A nested randomised trial of the effect of tranexamic acid on intracranial haemorrhage and infarction in traumatic brain injury (CRASH-3 trial intracranial bleeding mechanistic study): Statistical analysis plan

Abda Mahmood, Ian Roberts, Haleema Shakur-Still

Wellcome Open Research

Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach

Jack Williams, Ian Roberts, Haleema Shakur-Still, Fiona E Lecky, Rizwana Chaudhri, Alec Miners

BMJ Global Health

Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results

Raoul Mansukhani, Lauren Frimley, Haleema Shakur-Still, Linda Sharples & Ian Roberts

Trials

Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial

Amy Brenner, Antonio Belli, Rizwana Chaudhri, Timothy Coats, Lauren Frimley, Sabariah Faizah Jamaluddin, Rashid Jooma, Raoul Mansukhani, Peter Sandercock, Haleema Shakur-Still, Temitayo Shokunbi & Ian Roberts On behalf of the CRASH-3 trial collaborators

Critical Care

Does tranexamic acid improve outcomes in traumatic brain injury?

Abda Mahmood,Ian Roberts,Haleema Shakur,Tim Harris, Antonio Belli

BMJ

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial

The CRASH-3 trial collaborators

The Lancet

Want to hear from us?

Sign up to our trial newsletters and get the latest information on our trials.
Learn More
Menu